Piramal Pharma said while the YoY financials are not strictly comparable due to the non-inclusion of certain “non-common control transactions” with the Piramal Enterprises Ltd (PEL), it attributed the drop in EBITDA to higher operating expenses including raw material cost, energy prices, wage inflation, and marketing cost
Subscribe To Our Free Newsletter |